awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q41503997-A44AD184-569F-4EE5-8D0C-55F6A7BCEC0B
Q41503997-A44AD184-569F-4EE5-8D0C-55F6A7BCEC0B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41503997-A44AD184-569F-4EE5-8D0C-55F6A7BCEC0B
Clinician trialist rounds: 28. When RCT participants are lost to follow-up. Part 1: Why even a few can matter.
P2860
Q41503997-A44AD184-569F-4EE5-8D0C-55F6A7BCEC0B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41503997-A44AD184-569F-4EE5-8D0C-55F6A7BCEC0B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
780f1ca3b96abbb9335175f991fe6a8aa9e8ea31
P2860
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.